Bayer

Bayer Takes Legal Battle to the Supreme Court Over Roundup Litigation

2 months ago

In a continuation of its complex legal saga, Bayer AG has officially appealed to the United States Supreme Court concerning its ongoing Roundup litigation. This critical move comes as the company seeks to challenge a series of legal decisions that have held it accountable for claims linking its popular herbicide to severe health issues, including cancer.

Bayer Faces $2 Billion Jury Verdict Over Roundup Cancer Claims in Georgia

2 months ago

In a significant legal setback, Bayer AG has been ordered by a jury in Georgia to pay $2 billion in damages to a couple who alleged that their cancer was caused by the company's glyphosate-based herbicide, Roundup. The verdict follows a trial that highlighted the contentious and ongoing debate surrounding the safety of glyphosate, a chemical that has been under scrutiny due to its potential link to cancer.

Bayer Pursues Capital Raise Amidst Ongoing Legal Challenges

3 months ago

Bayer AG, the German pharmaceutical giant, is taking significant steps to manage its extensive legal challenges by seeking regulatory approval for a substantial capital increase. This decision comes as the company continues to face the financial repercussions from various lawsuits related to its herbicide Roundup, which has been linked to cancer claims.

Bayer Anticipates Declining Profits Amidst Weak Agricultural Pricing

3 months ago

Bayer AG, the German pharmaceuticals and life sciences giant, is bracing for a challenging financial landscape as it projects a drop in profits in 2025, primarily influenced by stagnant pricing in the farming sector. This forecast comes as a stark reminder of the ongoing pressures facing agricultural companies globally, despite increasing demand for food production in the face of population growth.

Trump Tariffs: A Looming Threat to Europe's Pharmaceutical Giants

3 months ago

In a shocking development that could reshape the landscape of the pharmaceutical industry in Europe, a new fiscal policy initiated by former President Donald Trump threatens significant financial implications for major pharmaceutical corporations across the continent. As the economic ramifications of these tariffs become clearer, industry experts are beginning to analyze which companies may be most vulnerable to these sweeping changes.

Bayer Ordered to Pay $100 Million Over Toxic PCB Contamination

4 months ago

In a significant legal blow, Bayer AG has been instructed by a jury to pay a staggering $100 million in damages attributed to the contamination caused by polychlorinated biphenyls (PCBs) in residential areas. This ruling comes as part of a larger trend of litigation surrounding the chemical's legacy, which has plagued communities and sparked environmental health concerns across the United States.

Bayer Announces Shift in Strategy: Scaling Back Health Dealmaking to Address Debt

4 months ago

Bayer AG, the German pharmaceutical and life sciences giant, is set to reduce its focus on acquisitions within the health sector as part of a broader strategy to manage and lower its substantial debt burden. The announcement comes in response to pressures from investors and a need for a more disciplined financial approach, particularly following a series of costly deals and legal challenges the company has faced in recent years.

Bayer Secures EU Approval for Heart Drug, Mitigating Patent Worries

5 months ago

Bayer has recently received a significant endorsement from the European Union for its new heart medication, providing the company with much-needed momentum amidst ongoing concerns regarding patent expirations and market competition. This approval is seen as a pivotal moment for Bayer as it works to sustain its market position and boost its pharmaceutical division amidst an evolving landscape.